# Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

> **NCT00230217** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 94 (actual)

## Conditions studied

- Tumors
- Hyperuricemia
- Tumor Lysis Syndrome

## Interventions

- **DRUG:** Rasburicase (SR29142)

## Key facts

- **NCT ID:** NCT00230217
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2009-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230217, "Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00230217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*